Form 4: Director Michael Holder Exercises Cytek RSU Awards

Cytek Biosciences director Michael Holder acquired 1,454 shares of common stock through the vesting of restricted stock units.

Summary

• Director Michael Holder exercised 1,454 restricted stock units (RSUs) on May 18, 2026.
• Each RSU converted into one share of Cytek Biosciences, Inc. (CTKB) common stock.
• Following the transaction, the director holds a total of 16,721 shares of common stock directly.
• The transaction resulted in 9,457 remaining unvested derivative securities held by the director.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents the standard fulfillment of previously granted equity compensation to a director.

Positives

• Director maintains a direct equity stake in the company, aligning interests with shareholders.

Negatives

• None identified; this is a routine equity compensation settlement.

Risks

• None identified; this is a standard administrative filing regarding equity compensation.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a disclosure of insider equity transactions.

Industry Context

StockSavvy.ai notes that routine RSU vesting for directors is standard practice in the biotechnology sector to ensure long-term alignment between board members and company performance.

Comparison to Industry Standards

• The transaction follows standard equity compensation structures common among mid-cap life sciences companies.
• The vesting schedule is consistent with typical director compensation packages in the NASDAQ-listed biotech space.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine equity settlement.

Next Steps

• Future vesting of remaining 9,457 restricted stock units according to the established schedule.

Key Dates

Keywords

CTKB, Cytek Biosciences, Form 4, Insider Trading, Equity Compensation, Director Ownership